Latest studies
Every paper our editors flag with a plain-language note and an evidence rating. Filter by evidence, species, or design to find what actually applies to you.
- Study · KisspeptinWeak / none
Rapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices.
This study is not a clinical or pharmacological investigation — it is a doping-control analytical methods paper, and should be read as such. Researchers developed and validated a streamlined workflow capable of detecting 54 prohibited substances, including BPC-157 and TB-500, across dried blood spots, serum, and plasma using a single microextraction step followed by liquid chromatography coupled with high-resolution mass spectrometry. The analytical performance was satisfactory by laboratory standards: detection limits ranged from 0.05–1.25 ng/mL, no carry-over was observed, and matrix effects were modest (5–33%). Notably, dried blood spot matrices preserved all compounds for the full study duration under non-refrigerated conditions — a meaningful practical advantage for anti-doping sample logistics. For readers tracking BPC-157 and TB-500 specifically: the stability data are striking. Both peptides showed complete degradation in serum within one week at room temperature or refrigerator temperature — a finding with direct implications for detection windows in anti-doping contexts. Dried matrices retained detectability throughout. This paper contributes nothing to the...
The Analystn=——Jun 22, 2026 - Study · BPC-157Weak / none
BPC-157 and Its Novel Hybrid Analogs as Inhibitors of Acetylcholinesterase.
This in-vitro study is the first to characterise BPC-157 and two rationally designed hybrid analogs — CIARA-1 and CIARA-2 — as reversible competitive inhibitors of acetylcholinesterase (AChE), an enzyme central to cholinergic signalling and a well-established drug target in Alzheimer's disease. Researchers found that CIARA-1 showed the highest inhibitory potency (Ki = 0.24 mM; IC50 = 2.52 mM), followed by CIARA-2 and BPC-157 itself, with findings consistent with molecular modelling predictions. The critical caveat is one the authors state plainly: potency across all three compounds is substantially lower than clinically used AChE inhibitors such as donepezil or galantamine. An IC50 in the low-millimolar range is orders of magnitude weaker than approved drugs operating in the nanomolar range. This is an early-stage mechanistic signal, not evidence of therapeutic applicability. For BPC-157's broader evidence landscape, this study opens a genuinely novel mechanistic avenue — the peptide's potential to interact with cholinergic pathways had not been formally explored prior to this work. However, these are in-vitro findings only; human data are entirely absent. The authors...
International journal of molecular sciencesn=—In vitroMay 30, 2026 - Study · BPC-157Weak / none
Unilateral Adrenalectomy, and the Stable Pentadecapeptide BPC 157 as Therapy in Rats-A Cytoprotection Approach.
This preclinical rat study from Pharmaceuticals examines BPC 157's effects following unilateral adrenalectomy — surgical removal of one adrenal gland — a model designed to provoke vascular failure, multi-organ injury, and thrombotic cascades. Researchers reported that BPC 157, administered orally at two doses (10 µg/kg and 10 ng/kg), was associated with attenuation of arrhythmias, hypertension in multiple vascular beds, organ hemorrhage, and markers of oxidative stress, alongside upregulation of NOS1-3 and VEGF-A expression. The proposed mechanistic pathway — NO-system modulation and oxidative stress counteraction — aligns with the dominant hypothesis in BPC 157's broader preclinical literature. These are preclinical findings in rats; human data are needed before any clinical conclusions can be drawn. The study's value is primarily mechanistic: it extends BPC 157's documented vascular cytoprotection signal into a hormonal-surgical injury model and suggests collateral circulatory reactivation as a plausible pathway. Caveats are substantial. This work originates from Sikiric et al., the primary research group driving BPC 157 investigation — independent replication is absent. No...
Pharmaceuticals (Basel, Switzerland)n=—AnimalMay 30, 2026 - Study · BPC-157Weak / none
Protective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury.
This preclinical study in 24 male Wistar rats adds to BPC-157's growing mechanistic portfolio by testing it in a lower-limb ischemia-reperfusion (I/R) model. Researchers found that a single intraperitoneal dose of BPC-157 (20 µg/kg), given at the end of a 45-minute ischemic period, was associated with reduced oxidative stress markers (MDA, TOS), restored antioxidant capacity (SOD, TAS), downregulated pro-apoptotic signaling (p53, Bax, Caspase-3), reduced IL-6 immunoreactivity, and partial restoration of VEGF expression — with histology showing improved muscle architecture and less fibrosis. The effect sizes appear meaningful within this model, though the group size of six animals per arm limits statistical confidence. The study is well-structured for its design, incorporating both biochemical and gene-expression endpoints, but it is strictly a rodent preclinical model. Extrapolation to human peripheral arterial disease requires considerable caution. BPC-157's regulatory standing in the US remains unsettled, and the broader evidence base — while mechanistically compelling in animals — lacks the human RCT data needed to draw clinical conclusions. This study reinforces plausible...
Scientific reportsn=—AnimalMay 28, 2026 - Study · BPC-157Weak / none
BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers.
This narrative review in Pharmaceutics takes a sobering, pharmaceutical-science lens to BPC-157 — a peptide that has accumulated three decades of preclinical literature while remaining, by the authors' assessment, fundamentally underdeveloped as a drug candidate. The review's core argument is precise and worth stating clearly: the bottleneck is not biological activity, but the absence of basic pharmaceutical infrastructure — no validated formulation, no BCS classification, no formal excipient compatibility data, and human pharmacokinetic evidence drawn from just two subjects across uncontrolled pilot work. A narrative review carries inherent limitations: no formal quality appraisal was applied to included studies, and the conclusions reflect the authors' synthesis rather than a pre-registered systematic process. Readers should weight it as expert commentary, not a meta-analytic verdict. The sub-30-minute plasma half-life finding — confirmed preclinically across two species and in a two-subject human pilot — is the study's sharpest translational signal. The prolonged biological effects observed in animal models despite rapid plasma clearance represent a genuine...
Pharmaceuticsn=——May 20, 2026 - Study · BPC-157Weak / none
Endothelium-Dependent Nitric Oxide-Mediated Vasorelaxant Effects of BPC 157 in Human Internal Mammary Artery.
This in-vitro study provides the first direct evidence that BPC-157 can induce vasorelaxation in human arterial tissue — specifically residual internal mammary artery segments collected from 12 patients undergoing coronary bypass surgery. Researchers found a concentration-dependent reduction in phenylephrine-induced contraction, with significantly greater relaxation in endothelium-intact rings compared to denuded ones. NOS inhibition with L-NAME substantially attenuated these effects, implicating the endothelial nitric oxide pathway as the primary mediating mechanism. A residual relaxation effect persisted under NOS blockade, suggesting additional, as-yet-uncharacterised pathways. The finding matters because BPC-157's vasodilatory effects had previously been demonstrated only in animal models; this is the first mechanistic signal in human tissue. That said, ex-vivo ring preparations are not equivalent to intact vascular physiology — there is no circulating milieu, no autonomic tone, and no systemic pharmacokinetics. The sample size of 12 donors is small, and the study cannot establish dose relevance for any in-vivo context. This work adds a meaningful mechanistic datapoint to...
Journal of clinical medicinen=—In vitroMay 2, 2026 - Study · SemaglutideMixed
Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications.
A structured narrative review in a peer-reviewed orthopaedic journal surveying injectable peptides promoted for musculoskeletal recovery. Narrative reviews are synthesis, not new data, and this one is graded Level V (expert synthesis over predominantly low-quality evidence), so it frames the landscape rather than settling any single question. The authors reported that GLP-1 receptor agonists such as semaglutide are the only class here with reproducible randomised evidence of symptomatic improvement in knee osteoarthritis, and that the benefit appears mediated by weight loss and possible anti-inflammatory effects rather than any structural cartilage change, which remains unproven. Crucially, the review places the regenerative and growth-hormone-axis peptides, BPC-157, thymosin derivatives, CJC-1295, ipamorelin and tesamorelin, as investigational, with uncertain safety, product-quality concerns and anti-doping restrictions. Its bottom line is restraint: outside approved metabolic agents for their indicated uses, injectable peptides in sports medicine remain experimental and warrant counselling on uncertain efficacy and contamination and doping risks.
JBJS reviewsn=——May 1, 2026 - Study · SS-31Weak / none
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.
This narrative review in Sports Medicine surveys the pharmacological profiles, regulatory standing, and safety data for eleven peptides marketed to athletes and patients seeking injury recovery — ranging from FDA-approved tesamorelin to unapproved compounds such as BPC-157, TB-500, and MOTS-c. The authors' central finding is that a substantial regulatory gap exists: while some peptides (tesamorelin, sermorelin historically) have cleared rigorous approval processes for specific indications, many others circulate in a gray market supported primarily by animal-model data and amplified by social media. A narrative review design is worth flagging. Unlike a systematic review or meta-analysis, it does not involve exhaustive literature search protocols or pooled effect-size estimates, which means it reflects editorial judgment about which evidence to emphasise. That is appropriate for a broad landscape survey but limits the precision of any efficacy conclusions. The key caveat — which the authors acknowledge directly — is that favorable preclinical signals in rodent tissue-repair and metabolic models do not reliably translate to human outcomes. The review also raises an...
Sports medicine (Auckland, N.Z.)n=——Apr 12, 2026 - Study · Thymosin Alpha-1Weak / none
Peptide Therapies in Thyroid Health: Emerging Applications in Endocrine and Immune Modulation.
This narrative review in Integrative Medicine surveys the mechanistic rationale and existing evidence for several peptides — thymosin alpha-1, thymosin beta-4, BPC-157, and growth hormone secretagogues — as potential adjuncts in thyroid disorders, particularly Hashimoto's thyroiditis. The authors' own framing is appropriately cautious: the evidence base consists primarily of preclinical investigations, mechanistic studies, and early exploratory clinical reports, not thyroid-focused randomised controlled trials. As a narrative review, this study synthesises existing literature rather than generating new data — which means its conclusions are shaped by what research already exists, including its gaps. Narrative reviews are also susceptible to selection bias in ways that systematic reviews with predefined search protocols are not. The peptide context reinforces the authors' restraint. Thymosin alpha-1 carries the strongest human evidence base of the group, but that evidence covers hepatitis and oncology indications — not thyroid disease. BPC-157 remains almost entirely preclinical. The thyroid-specific evidence gap the review identifies is real and significant. Readers should...
Integrative medicine (Encinitas, Calif.)n=——Apr 1, 2026 - Study · BPC-157Weak / none
From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management.
This narrative review synthesises preclinical and limited human evidence on BPC-157's roles in tissue repair and pain modulation. As a review — not a controlled trial — it aggregates existing data rather than generating new findings, so readers should weigh it accordingly: it reflects the current literature's shape, including its significant gaps. The review's core claim is that BPC-157 influences angiogenesis, collagen synthesis, fibroblast activity, and nitric oxide pathways across multiple tissue types. These mechanistic signals are well-documented in rodent models. The human data the review cites, however, are described as small pilot studies — a characterisation consistent with the broader evidence landscape, in which no large-scale RCTs exist as of mid-2026. A substantive caveat: narrative reviews are inherently selective. Without a systematic search strategy or meta-analytic framework, the review's conclusions can reflect the authors' priors. The authors themselves acknowledge inconsistent preparation standards and limited clinical validation — appropriate transparency. The review also notes BPC-157's evolving regulatory status. In the US, the compound was removed...
International journal of molecular sciencesn=——Mar 22, 2026 - Study · BPC-157Weak / none
Stable Gastric Pentadecapeptide BPC 157 as a Therapy of Severe Electrolyte Disturbances in Rats.
This narrative review, published in Current Neuropharmacology, synthesises preclinical findings on BPC 157's effects across four electrolyte disturbance models — hyperkalemia, hypokalemia, hypermagnesemia, and lithium intoxication — conducted primarily in rats and in HEK293 cell lines. The breadth of effects reported is notable: researchers describe attenuation of arrhythmias, muscle paralysis, vascular failure, and lethality across multiple induction models. In vitro, BPC 157 appeared to counteract both depolarisation and hyperpolarisation depending on the electrolyte context. As a narrative review of animal and cell-based work, this sits near the base of the clinical evidence hierarchy. No human data are presented. The review draws heavily from a single research group, which limits independent corroboration — a recurring limitation in the BPC 157 literature broadly. Mechanistic plausibility is offered via NO-system and vascular pathway hypotheses, but causal chains remain incompletely characterised. For readers tracking BPC 157's evidence landscape, this review extends the peptide's preclinical profile into electrolyte pharmacology — a less-explored domain than its...
Current neuropharmacologyn=——Mar 13, 2026 - Study · BPC-157Weak / none
Cytoprotection as a Unifying Strategy for Hemorrhage and Thrombosis: The Role of BPC 157 and Related Therapeutics.
This narrative review from Pharmaceuticals synthesizes preclinical and conceptual evidence around BPC 157, proposing cytoprotection as a framework that could theoretically address both hemorrhage and thrombosis simultaneously — what the authors call the hemorrhage-thrombosis paradox. The central claim is that, in rodent models, BPC 157 can reduce both bleeding and clotting without directly altering the coagulation cascade as measured by aggregometry and thromboelastometry. This is a narrative review, not a controlled trial, which carries significant interpretive weight. Narrative reviews synthesize selectively; they cannot establish causation or effect size, and are vulnerable to author framing. The authors themselves acknowledge reliance on preclinical models and the necessity of clinical validation. The finding sits squarely within BPC 157's existing evidence landscape: a well-characterized rodent literature with no large-scale human RCTs published as of mid-2026. The bidirectional vascular regulation hypothesis is mechanistically interesting — particularly the proposed NO system modulation and endothelial integrity preservation — but remains unvalidated in humans. Readers...
Pharmaceuticals (Basel, Switzerland)n=——Mar 12, 2026 - Study · BPC-157Weak / none
Tendon, Ligament, and Muscle Injury, Osteotendinous, Myotendinous, and Muscle-to-Bone Junction Therapy Perspectives with Growth Factors and Stable Gastric Pentadecapeptide BPC 157-A Review.
This narrative review, published in Pharmaceuticals (Basel), synthesizes preclinical evidence comparing BPC-157, platelet-rich plasma (PRP), and several growth factors (PDGF, TGF-β1, IGF-1, FGF, VEGF, BMPs) for tendon, ligament, muscle, and junctional injury recovery. The review's central argument — that BPC-157 acts as a broad cytoprotective mediator without requiring scaffolds or carriers — is an interesting framing, but readers should register the study design carefully: this is a narrative review, not a meta-analysis or RCT, and the underlying evidence base is overwhelmingly rodent-model data. The review reports that certain growth factors showed limited or no efficacy at musculotendinous junctions, whereas BPC-157 demonstrated consistent signals across systemic and local administration routes in rat studies. The translational gap, however, is substantial. As the peptide context confirms, no large-scale human RCTs exist for BPC-157 as of mid-2026, and its regulatory status in the US is unsettled. The authors' own call for further clinical studies tacitly acknowledges how early this evidence remains. Mechanistic signals from rat models are hypothesis-generating, not...
Pharmaceuticals (Basel, Switzerland)n=——Feb 12, 2026 - Study · BPC-157Weak / none
BPC157 drives angiogenesis through FBXO22-dependent stabilization of BACH1.
This in-vitro study proposes a specific molecular mechanism for BPC-157's well-documented proangiogenic effects — a mechanistic gap that has long complicated its translational narrative. Researchers report that BPC-157 interacts with the E3 ubiquitin ligase adaptor FBXO22 via its third-position proline residue, forming a complex that blocks the proteasomal degradation of the transcription factor BACH1. The resulting BACH1 accumulation was associated with increased proliferation and tube-forming capacity in vascular endothelial cells. The finding is mechanistically specific and, if reproducible, would constitute a genuinely novel axis — BPC157-FBXO22-BACH1 — distinct from the NO-system and growth-hormone-receptor pathways previously proposed. That specificity is worth noting. However, this is a cell and tissue study. These are preclinical, mechanistic signals; human data are needed before clinical conclusions can be drawn. In-vitro tube-forming assays and proliferation metrics are several steps removed from physiologically meaningful angiogenesis in a living system. The study does not report adverse events, as none are applicable in this model. Given that BPC-157's broader...
Cell communication and signaling : CCSn=—In vitroJan 29, 2026 - Study · BPC-157Weak / none
Conventional Antiarrhythmics Class I-IV, Late INa Inhibitors, IKs Enhancers, RyR2 Stabilizers, Gap Junction Modulators, Atrial-Selective Antiarrhythmics, and Stable Gastric Pentadecapeptide BPC 157 as Useful Cytoprotective Therapy in Arrhythmias.
This narrative review from Pharmaceuticals proposes 'cytoprotection' as a conceptual framework for evaluating antiarrhythmic drugs, positioning BPC-157 as a candidate for what the authors call 'full cytoprotection/wide-range homeostasis.' The authors survey conventional antiarrhythmics (Classes I–IV) alongside newer targets, then argue BPC-157 occupies a uniquely favorable profile based on preclinical data. The study design matters here: this is a narrative review, not a systematic review or meta-analysis, and the framing is openly hypothesis-generating. The authors themselves acknowledge that BPC-157 data derive predominantly from rodent models and HEK293 cell studies. No cardiac-specific human trial data are presented. The BPC-157 evidence landscape is, per the peptide's broader context, preclinical-dominant. The review's claim that no adverse effects have appeared in available human trials is accurate but narrow — those trials were non-cardiac and small. Extrapolating a cardiac cytoprotective profile from that is a significant inferential step the authors wisely flag as requiring translational expansion. The in vitro HEK293 findings on membrane stabilization are...
Pharmaceuticals (Basel, Switzerland)n=——Jan 29, 2026 - Study · BPC-157Weak / none
Fourier Transform Infrared Spectroscopic Characterization of Aortic Wall Remodeling by Stable Gastric Pentadecapeptide BPC 157 After Unilateral Adrenalectomy in Rats.
This preclinical study applies Fourier Transform Infrared (FTIR) spectroscopy — a technique that probes molecular structure in tissue — to examine how BPC 157 affects aortic wall composition in rats following unilateral adrenalectomy. Researchers found that a single oral dose of BPC 157 (10 ng/kg) produced statistically separable spectral signatures in aortic tissue at 15 minutes, 5 hours, and 24 hours post-surgery, with the main differences appearing in protein-related bands (amide I and amide II, consistent with collagen and elastin) and lipid membrane regions. The methodology is novel — FTIR paired with machine-learning discriminant analysis (SVMDA and PCA) is an unusual but legitimate approach for detecting early molecular changes in tissue. That said, spectral separation in a machine-learning model is not the same as demonstrated functional benefit; the study characterises molecular signatures, not physiological outcomes. Critical caveats apply. This is a rodent model with a small number of time points and no human data. The mechanistic interpretation — that spectral changes reflect 'extracellular matrix reinforcement and membrane preservation' — is plausible but...
Pharmaceuticals (Basel, Switzerland)n=—AnimalJan 22, 2026 - Study · BPC-157Weak / none
Tracheocutaneous Fistula Resolved by Pentadecapeptide BPC 157 Therapy Through the NO-System-Triple NO-Agent Approach in Rats.
This 7-day rat study from Sikiric's group — the same prolific team behind most of the BPC-157 preclinical literature — examined whether BPC-157 could accelerate closure of surgically created tracheocutaneous fistulas and how that effect interacts with the nitric oxide (NO) system. Results showed that untreated control animals developed severe respiratory distress, open-mouth breathing, cyanosis, and failed wound healing, while BPC-157-treated rats (across both oral and intraperitoneal routes, at µg and ng doses) showed macroscopic and microscopic fistula closure alongside reduced clinical distress markers. The study also reported that BPC-157 appeared to modulate both NO and oxidative stress (MDA) levels in fistula tissue, and could counteract the effects of pharmacological NO blockade or over-activation. These are preclinical findings in a rat model; human data are needed before clinical conclusions can be drawn. The 7-day window is short, the model is highly specific, and all work originates from one research group — independent replication is absent. The mechanistic framing around the NO system is consistent with the broader BPC-157 literature, which is almost entirely...
Pharmaceuticals (Basel, Switzerland)n=—AnimalJan 14, 2026 - Study · TesamorelinWeak / none
Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.
This narrative review in the American Journal of Sports Medicine takes an appropriately cautious inventory of injectable peptide therapy for orthopaedic and sports medicine — a field where patient demand has outpaced clinical evidence considerably. The authors surveyed BPC-157, TB-4/TB-500, CJC-1295 plus ipamorelin, tesamorelin, and GHK-Cu via PubMed and found a consistent pattern: promising preclinical signals, thin or absent human data, and unresolved questions around dosing, frequency, and duration for every compound reviewed. The review's conclusions align well with the broader evidence landscape for these peptides. BPC-157's lone human data point is a methodologically limited case series. Tesamorelin, the most regulation-hardened compound in the group with FDA approval and Phase III RCT backing, earned that standing for HIV-associated lipodystrophy — a narrow indication with no orthopaedic carryover. The murine muscle data for CJC-1295 plus ipamorelin is mechanistically interesting but cannot be extrapolated to clinical use. As a narrative review, this paper synthesises existing literature rather than generating new data — it reflects the state of evidence rather than...
The American journal of sports medicinen=——Jan 1, 2026 - Study · DSIPWeak / none
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.
This narrative review, published in the Journal of the American Academy of Orthopaedic Surgeons: Global Research & Reviews, surveys the mechanistic rationale for using therapeutic peptides — including BPC-157, TB-500, GHK-Cu, ipamorelin, CJC-1295, tesamorelin, sermorelin, semax, selank, and epitalon — in orthopaedic and musculoskeletal contexts. As a narrative review, it synthesises existing literature rather than generating new data; it carries no experimental controls, no patient cohort, and no statistical analysis of outcomes. Readers should weight it as an expert-curated overview, not as clinical evidence. The review's own authors acknowledge the central limitation plainly: preclinical findings are promising, but clinical trials are currently lacking. That candid admission matters. For most peptides covered — BPC-157, TB-500, ipamorelin, and epitalon in particular — the mechanistic picture is built almost entirely on rodent and in-vitro models. Tesamorelin is the notable exception, carrying FDA approval for HIV-associated lipodystrophy on the basis of Phase III RCT data, though that evidence does not transfer to orthopaedic applications. The review is useful as a...
Journal of the American Academy of Orthopaedic Surgeons. Global research & reviewsn=——Jan 1, 2026 - Study · TirzepatideWeak / none
Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.
This narrative review from Frontiers in Aging maps nine therapeutic peptides across aging-related domains — metabolic function, telomere biology, tissue repair, neuroprotection, GH modulation, and sexual function. The authors drew on 20 primary sources selected from PubMed, Scopus, and regulatory databases through January 2026. The core finding is an evidence stratification most readers of this space already sense: FDA-approved agents (tirzepatide, bremelanotide) rest on large-scale registration-quality trial data, while investigational peptides — epitalon, BPC-157, TB-500, Semax, GHK-Cu, CJC-1295, ipamorelin — show mechanistically interesting but methodologically limited signals, predominantly from preclinical models or small, often non-replicated studies. The critical caveat is the design itself. Narrative reviews are synthesis without meta-analytic rigour; the 20-source selection pool is modest for a field this broad, and the review does not appear to have applied formal quality-grading criteria. Conclusions therefore reflect the authors' judgment rather than a systematic evidence synthesis. For readers tracking investigational peptides: the review adds conceptual framing...
Frontiers in agingn=——Jan 1, 2026 - Study · BPC-157Weak / none
Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing.
Among the BPC-157 reviews, this scoping review is unusually even-handed. It catalogues the mechanistic pathways implicated in animal work (VEGFR2, Akt-eNOS/nitric-oxide signalling, ERK1/2, anti-inflammatory effects) and states the central problem plainly: despite broad preclinical support, human data are extremely limited, only three small pilot studies (intra-articular knee pain, interstitial cystitis, and an IV safety/pharmacokinetics study), with no adverse effects reported but no large trials. The authors conclude BPC-157 should be considered investigational and approached with caution. That framing aligns with the wider evidence landscape: consistent rodent findings, but insufficient human evidence to establish benefit or safety for musculoskeletal use. Useful as an orientation to the field. BPC-157 is not FDA-approved, is banned in sport, and was removed from the FDA Category-2 compounding list.
Current reviews in musculoskeletal medicinen=——Dec 1, 2025 - Study · BPC-157Weak / none
Challenge of Corneal Ulcer Healing: A Novel Conceptual Framework, the "Triad" of Corneal Ulcer Healing/Corneal Neovascularization/Intraocular Pressure, and Avascular Tendon Healing, for Evaluation of Corneal Ulcer Therapy, Therapy of Neovascularization, Glaucoma Therapy, and Pentadecapeptide BPC 157 Efficacy.
This is a conceptual review from the cytoprotection school, not new primary data. It proposes a unifying 'triad' linking corneal ulcer healing, abnormal vessel growth and eye pressure, and extends it to avascular tendon, with BPC-157 offered as the leading example. The BPC-157 findings it cites (normalized intraocular pressure in glaucomatous rats, preserved corneal transparency, tendon-injury models) are preclinical rodent work; these are mechanistic signals, not clinical proof, and human data are needed before conclusions can be drawn. Readers should also note that much of the BPC-157 literature originates from a single research group with disclosed commercial interests and limited independent replication. Weight this as a hypothesis-framing argument rather than evidence that the peptide works for any eye or tendon condition in people. BPC-157 is not FDA-approved and was removed from the FDA Category-2 compounding list.
Pharmaceuticals (Basel, Switzerland)n=——Nov 28, 2025 - Study · BPC-157Weak / none
BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Comment on Józwiak et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals 2025, 18, 185.
This is a rebuttal review, not a primary study: the authors defend BPC-157 against a separate critical review (Jozwiak et al.) that raised concerns about tumour promotion, nitric-oxide-driven free-radical damage, and neurodegeneration. They argue that in animal models BPC-157 instead controls angiogenesis and the NO system and counters Parkinson's- and Alzheimer's-like changes, and they cite a favourable safety signal (no lethal dose reached in toxicology). Read this as scientific debate rather than settled fact. The claims on both sides rest almost entirely on rodent and in-vitro work; these are mechanistic signals, and human data are needed before any clinical conclusion. Notably, much of the supportive literature comes from one research group with disclosed commercial interests, so independent replication matters here. BPC-157 remains non-FDA-approved and was removed from the FDA Category-2 compounding list.
Pharmaceuticals (Basel, Switzerland)n=——Sep 28, 2025 - Study · BPC-157Weak / none
Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.
A very small human safety signal, and important to size correctly. This pilot gave intravenous BPC-157 (10 mg then 20 mg) to just two adults over three days, tracking bloodwork and vital signs. No changes in cardiac, liver, kidney, thyroid or glucose markers were seen, and no side effects were reported; the authors describe it as tolerated. But with only two participants, both of whom had received BPC-157 before, this cannot establish safety in any general sense, and it says nothing about efficacy. It is best read as a first-step tolerability observation that the authors themselves say must be confirmed in larger studies. BPC-157's human evidence base remains limited to a handful of small pilots. It is not FDA-approved and was removed from the FDA Category-2 compounding list.
Alternative therapies in health and medicinen=—HumanSep 1, 2025 - Study · BPC-157Weak / none
Editorial Commentary: Testosterone, Growth Hormone, and Vitamin D Supplementation Is Not Routinely Indicated for Orthopaedic Surgery Patients.
This is an orthopaedic editorial commentary about testosterone replacement therapy, not a study of BPC-157. BPC-157 appears only as a passing mention and is mischaracterised as a growth hormone, which it is not; it is a synthetic pentadecapeptide. The piece offers no data on BPC-157 and reaches no conclusion about it. Its central argument is that TRT and related supplements are not indicated for routine perioperative use in orthopaedic patients. For readers tracking BPC-157, the takeaway is narrow: the compound is entering clinical conversation around surgical recovery, but this commentary supplies no evidence for that use. BPC-157's own evidence base remains preclinical, drawn from rodent tendon, gastrointestinal and wound-healing models and largely from a single conflicted research group, with no published human efficacy trials. Weight this as a sign of clinical awareness, not as support for any BPC-157 application.
Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Associationn=——Aug 1, 2025 - Study · BPC-157Weak / none
Concerning BPC-157, a natural pentadecapeptide, that acts as a cytoprotectant and is believed to protect the gastro-intestinal tract (GIT).
Little can be said here: the abstract is a single sentence noting that this article discusses a lengthy 2024 review by Sikiric and 21 co-authors in Inflammopharmacology. No original findings, methods, or data are presented in the abstract provided, so this should be read as commentary on the broader cytoprotection literature rather than as a study reporting results. That broader BPC-157 literature is predominantly preclinical (rodent and in-vitro), concentrated in a single research group with disclosed commercial interests, and lacks large human trials. Readers should not draw any efficacy or safety conclusion from this item itself. BPC-157 is not FDA-approved and was removed from the FDA Category-2 compounding list.
Inflammopharmacologyn=——Aug 1, 2025 - Study · BPC-157Weak / none
Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.
A systematic review worth reading for its transparency about evidence quality. Of 544 records, 36 studies met inclusion, but 35 were preclinical and only one was clinical, and the authors grade the body of work as level IV-V (the weakest tiers). In animal models BPC-157 was associated with improved functional, structural and biomechanical outcomes across muscle, tendon, ligament and bone, plausibly via growth-hormone-receptor and angiogenic pathways. The single human signal is a retrospective series in which 7 of 12 patients reported over six months of relief after intra-articular injection for chronic knee pain: hypothesis-generating at best, uncontrolled and small. Preclinical safety studies showed no adverse effects, but the authors stress no clinical safety data exist and flag contamination risk from unregulated sourcing. BPC-157 is not FDA-approved and is banned in professional sport.
HSS journal : the musculoskeletal journal of Hospital for Special Surgeryn=——Jul 31, 2025 - Study · BPC-157Weak / none
Stable Gastric Pentadecapeptide BPC 157 as a Therapy and Safety Key: A Special Beneficial Pleiotropic Effect Controlling and Modulating Angiogenesis and the NO-System.
This review largely restates the cytoprotection group's defence of BPC-157, closely mirroring their companion paper: in animal models the peptide is argued to regulate, rather than dangerously amplify, angiogenesis and the nitric-oxide system, to counter Parkinson's- and Alzheimer's-like changes, and to show anti-tumour signals in vivo and in vitro, alongside a favourable toxicology profile (no lethal dose reached). This is an advocacy review, not new primary data. Every claim rests on preclinical rodent and cell work; these are mechanistic signals, and human data are needed before clinical conclusions. Given that much of this literature originates from a single group with disclosed commercial interests, independent replication is the key missing ingredient. BPC-157 is not FDA-approved and was removed from the FDA Category-2 compounding list.
Pharmaceuticals (Basel, Switzerland)n=——Jun 19, 2025 - Study · BPC-157Weak / none
Acute Compartment Syndrome and Intra-Abdominal Hypertension, Decompression, Current Pharmacotherapy, and Stable Gastric Pentadecapeptide BPC 157 Solution.
Another cytoprotection-concept review, focused on abdominal compartment syndrome and intra-abdominal hypertension, which are severe, life-threatening surgical conditions. It summarises animal work in which BPC-157 is described as rapidly opening collateral blood-flow pathways (an 'azygos vein bypass') and limiting multi-organ and vascular failure during compression and reperfusion. These are striking claims, but they are drawn from rodent models and framed within a single theoretical paradigm; they are mechanistic signals, not clinical evidence, and human data are needed before any translation. The severity of the conditions discussed makes the absence of controlled human trials especially important to keep front of mind. Readers should weight this as a research hypothesis. BPC-157 is not FDA-approved and was removed from the FDA Category-2 compounding list.
Pharmaceuticals (Basel, Switzerland)n=——Jun 10, 2025 - Study · BPC-157Weak / none
Protective Effects of BPC 157 on Liver, Kidney, and Lung Distant Organ Damage in Rats with Experimental Lower-Extremity Ischemia-Reperfusion Injury.
A genuine preclinical efficacy study, not a review. In 24 male Wistar rats subjected to lower-limb ischemia-reperfusion, animals given BPC-157 showed significantly less histological damage in kidney, lung and liver tissue and higher antioxidant activity than controls. Because this is a randomized, sham-controlled rodent design with defined endpoints, it is a cleaner signal than the narrative reviews that dominate this literature, but it remains a small, single-model animal study. These are mechanistic findings; human data are needed before clinical conclusions can be drawn, and the effect on distant-organ protection has not been tested in people. It fits the broader pattern of consistent BPC-157 tissue-protection signals in rodents. BPC-157 is not FDA-approved and was removed from the FDA Category-2 compounding list.
Medicina (Kaunas, Lithuania)n=—AnimalFeb 8, 2025 - Study · BPC-157Weak / none
Injectable Therapeutic Peptides-An Adjunct to Regenerative Medicine and Sports Performance?
This is a commentary aimed at orthopaedic surgeons, not a data study. It flags the rapid, largely unregulated growth of injectable-peptide use among athletes and bodybuilders, with BPC-157 singled out as the leading example, and urges clinicians to stay current on the pharmacokinetics, safety, legal and ethical issues. Tellingly, the authors note there is scarce orthopaedic literature actually investigating clinical outcomes for these peptides in tendon, muscle and cartilage injury. Read it as a professional-awareness piece describing a market trend and its risks, not as evidence of benefit. The underlying BPC-157 human evidence remains limited to a few small pilots; efficacy for sports or joint injury is not established. BPC-157 is not FDA-approved, is banned in sport, and was removed from the FDA Category-2 compounding list.
Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Associationn=——Feb 1, 2025 - Study · BPC-157Weak / none
Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review.
A literature-and-patent review that is comparatively measured. It describes BPC-157's wide-ranging effects across preclinical models (tissue injury, inflammatory bowel models, CNS disorders) and notes a generally favourable reported side-effect profile, while stating plainly that the compound is not FDA-approved and lacks sufficient comprehensive human clinical studies. It also documents the regulatory and commercial context: a temporary 2022 WADA ban (no longer listed) and a surge of patent activity and online sales. Read this as a map of the field and its commercial momentum rather than evidence of benefit. As with the wider literature, the underlying data are preclinical; these are mechanistic signals, and human data are needed. Note this is the review that companion 'comment' papers in this batch were written to rebut.
Pharmaceuticals (Basel, Switzerland)n=——Jan 30, 2025 - Study · BPC-157Weak / none
Stable Gastric Pentadecapeptide BPC 157 as Therapy After Surgical Detachment of the Quadriceps Muscle from Its Attachments for Muscle-to-Bone Reattachment in Rats.
A detailed rodent surgical study reporting that oral BPC-157 (10 microgram and 10 ng/kg/day) was associated with muscle-to-bone reattachment after quadriceps detachment, where untreated animals showed healing failure with permanent knee contracture. The authors assessed outcomes across many timepoints using imaging, biomechanics and functional walking measures, a thorough design, and describe restored gait and new bone-muscle integration by three months. Still, this is a single-laboratory animal model; the findings are mechanistic signals, and human data are needed before any clinical claim. The very low doses and oral route are noteworthy but not directly translatable to people. Read it as an encouraging preclinical result within a literature that remains almost entirely non-human. BPC-157 is not FDA-approved and was removed from the FDA Category-2 compounding list.
Pharmaceuticsn=—AnimalJan 16, 2025 - Study · RetatrutideWeak / none
Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado.
This is a market-surveillance study, not a clinical trial, and its relevance here is regulatory rather than about efficacy. Surveying 93 Colorado websites selling compounded GLP-1 products, researchers found semaglutide advertised by nearly all and tirzepatide by many, with a small number offering combination products; BPC-157 appeared in just one. The authors specifically flag that BPC-157 has been determined by the FDA to be unsafe for compounding, and that many sites made misleading regulatory claims (implying FDA approval, or calling products 'generic'). For readers, the takeaway is about the direct-to-consumer marketplace and its claims, not about whether any of these peptides work. Semaglutide and tirzepatide are FDA-approved prescription drugs with large trial evidence; the compounded and combination versions described here fall outside that approved evidence base.
Journal of pharmaceutical policy and practicen=——Jan 1, 2025 - Study · BPC-157Weak / none
New studies with stable gastric pentadecapeptide protecting gastrointestinal tract. significance of counteraction of vascular and multiorgan failure of occlusion/occlusion-like syndrome in cytoprotection/organoprotection.
A broad cytoprotection-concept review that ranges across many organ systems, vascular recovery, eye, gut-brain, cardiac, musculoskeletal, with BPC-157 positioned as the central mediator. It references a phase II ulcerative colitis signal and favourable toxicology (no lethal dose), but the great majority of the evidence marshalled is preclinical rodent work organised around a single theoretical framework. These are mechanistic signals; human data are needed before clinical conclusions, and the one human trial reference is not sufficient to establish benefit. As with the rest of this group's output, the concentration of evidence in one COI-affected laboratory and limited independent replication are the key limitations. Read it as an ambitious synthesis of a hypothesis, not as proof. BPC-157 is not FDA-approved and was removed from the FDA Category-2 compounding list.
Inflammopharmacologyn=——Oct 1, 2024 - Study · BPC-157Weak / none
Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study.
A small uncontrolled pilot that reports dramatic results, which is exactly why it needs cautious reading. Twelve women with moderate-to-severe interstitial cystitis who had not responded to pentosan polysulfate received bladder-wall injections of BPC-157 (10 mg total) in a single procedure; 10 of 12 reported complete symptom resolution and the other 2 reported about 80% improvement, with no adverse events reported and no dropouts. But there was no placebo group, no blinding, a subjective questionnaire endpoint, and just 12 participants at a single private clinic, a design highly vulnerable to placebo effect and bias. This is a hypothesis-generating first report, not evidence of efficacy. BPC-157 is not FDA-approved for this or any indication and was removed from the FDA Category-2 compounding list; controlled trials would be needed to interpret these results.
Alternative therapies in health and medicinen=—HumanOct 1, 2024 - Study · BPC-157Weak / none
Stable Gastric Pentadecapeptide BPC 157 and Intestinal Anastomoses Therapy in Rats-A Review.
A single-topic review summarising rodent work in which BPC-157 is described as aiding the healing of surgically joined sections of gut (anastomoses) and closing various fistulas. The breadth of models cited is broad, but this is a narrative review from the cytoprotection school, drawing exclusively on animal studies; the findings are mechanistic signals, and human data are needed before any surgical conclusion. There is no controlled human trial of BPC-157 for anastomotic healing, and the concentration of this literature in a single group with disclosed commercial interests means independent replication is an open requirement. Weight it as a preclinical hypothesis about wound-healing biology rather than guidance for surgical care. BPC-157 is not FDA-approved and was removed from the FDA Category-2 compounding list.
Pharmaceuticals (Basel, Switzerland)n=——Aug 17, 2024 - Study · BPC-157Weak / none
The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity.
A speculative mechanistic review exploring whether BPC-157's wide-ranging effects might relate to neurotransmitter systems: dopamine, serotonin, glutamate, GABA, adrenergic, cholinergic and the NO system. The authors are candid that direct, conclusive evidence is lacking (BPC-157 does not meet the classic criteria for a neurotransmitter) and instead assemble an 'interconnected network' of indirect animal findings. That honesty is welcome, but it also means this is hypothesis-building, not demonstration: the underlying data are preclinical, these are mechanistic signals, and human data are needed. Readers interested in how BPC-157 might act on the nervous system will find a framework here, but no established receptor-level mechanism and no clinical evidence. BPC-157 is not FDA-approved and was removed from the FDA Category-2 compounding list.
Pharmaceuticals (Basel, Switzerland)n=——Apr 3, 2024